A progress report on reimbursement of biotherapy: prospects for the 1990s

Abstract

Reimbursement of cancer care associated with clinical trials continues to be a growing national concern. Cancer organizations have taken many actions to draw attention to an economic force with the potential to seriously hamper oncology research. Strategies are described that could prove useful to cancer care professionals as they attempt to influence reimbursement policies.